$5.57
5.03%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US67576A1007
Symbol
OCUL

Ocular Therapeutix Inc Stock News

Neutral
●
GlobeNewsWire
●
about 19 hours ago
BEDFORD, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company's new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to ...
Neutral
●
GlobeNewsWire
●
12 days ago
AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on submission package under 505(b)(2) pathway SOL-1 post-hoc analyses presented at AAO and Empire Forum show subjects without early persistent retinal fluid and fluid variability had b...
Neutral
●
GlobeNewsWire
●
15 days ago
BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to eight newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of empl...
Neutral
●
GlobeNewsWire
●
23 days ago
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.
Neutral
●
GlobeNewsWire
●
about one month ago
Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to fifteen newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of employment with Ocular under Ocular's 2019 Inducemen...
Neutral
●
GlobeNewsWire
●
2 months ago
BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient's acceptance of empl...
Neutral
●
GlobeNewsWire
●
2 months ago
Consistent with prior Type C Meeting, the Pre-NDA Meeting confirms Ocular's plan to submit AXPAXLI NDA based on SOL-1 Week 52 efficacy and safety, interim SOL-R safety, and confirmatory evidence AXPAXLI NDA submission for wet AMD remains on track for 4Q 2026 NDA submission to include subjects that have received multiple AXPAXLI injections in support of the Company's application for repeat dosin...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today